Huang Xue-Yan, Li Ting-Ting, Zhou Lin, Liu Tao, Xiong Liu-Lin, Yu Chang-Yin
Department of Neurology Affiliated Hospital of Zunyi Medical University Zunyi Guizhou China.
Institute of Neurological Disease and Department of Anesthesiology Translational Neuroscience Center, West China Hospital, Sichuan University Chengdu Sichuan China.
Ibrain. 2021 Mar 28;7(1):21-28. doi: 10.1002/j.2769-2795.2021.tb00060.x. eCollection 2021 Mar.
Study the principle and possible mechanism of Ginkgo biloba in the treatment of Alzheimer's disease (AD) which is based on network pharmacology.
The potential targets of active ingredients of Ginkgo biloba were collected by Traditional Chinese Medicine Integrated Database platform (TCMSP). TCMSP is a pharmacological system for drug discovery from Chinese herbal medicine. The disease targets of AD were searched and collected by the database of gene-disease associations (DisGeNET) and literature. The obtained targets were standardized by the UniProt database. STING network platform and Cytoscape were used to construct protein-protein interaction network (PPI) of the key targets. According to Materscape, we clarify the possible mechanism of action including Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) enrichment analysis.
The compound-target network contains 27 active ingredients, 191 related targets, 18 key targets, including PLAU, HMOX1, TNF, INSR, MPO, MAOB, IGF2, IL1B, ESR1, BCL2, ACHE, BAX, GSK3B, PPARG, SLC2A4, NOS3, CASP3, VEGFA. GO enrichment analysis has got a total of 640 GO items, including 609 biological process (BP) items (95.1%), 16 molecular function (MF) items (2.5%) and 15 cellular component (CC) items (2.4%). After KEGG enrichment, 44 pathways were obtained.
Through the construction of "component-target-pathway", GO biological function and KEGG pathway enrichment analysis were performed on core targets, and the possibility of Ginkgo biloba for the treatment of AD was explored from multiple targets and pathways, which provided a new approach for multi-target treatment.
基于网络药理学研究银杏叶治疗阿尔茨海默病（AD）的作用原理及可能机制。
通过中药整合数据库平台（TCMSP）收集银杏叶活性成分的潜在靶点。TCMSP是一个用于从中药中发现药物的药理系统。通过基因-疾病关联数据库（DisGeNET）和文献检索收集AD的疾病靶点。所得靶点通过UniProt数据库进行标准化。利用STRING网络平台和Cytoscape构建关键靶点的蛋白质-蛋白质相互作用网络（PPI）。根据Metascape，阐明包括京都基因与基因组百科全书（KEGG）通路和基因本体（GO）富集分析在内的可能作用机制。
化合物-靶点网络包含27种活性成分、191个相关靶点、18个关键靶点，包括PLAU、HMOX1、TNF、INSR、MPO、MAOB、IGF2、IL1B、ESR1、BCL2、ACHE、BAX、GSK3B、PPARG、SLC2A4、NOS3、CASP3、VEGFA。GO富集分析共获得640个GO条目，包括609个生物学过程（BP）条目（95.1%）、16个分子功能（MF）条目（2.5%）和15个细胞成分（CC）条目（2.4%）。KEGG富集后获得44条通路。
通过构建“成分-靶点-通路”，对核心靶点进行GO生物学功能和KEGG通路富集分析，从多个靶点和通路探索银杏叶治疗AD的可能性，为多靶点治疗提供了新途径。
